公开(公告)号：US20100159467A1

公开(公告)日：2010-06-24

申请号：US12633890

申请日：2009-12-09

申请人： CZESLAW WYCHOWSKI ,  GILLES DUVERLIE ,  JEAN DUBUISSON ,  ANDRÉ PILLEZ

发明人： CZESLAW WYCHOWSKI ,  GILLES DUVERLIE ,  JEAN DUBUISSON ,  ANDRÉ PILLEZ

IPC分类号： C12Q1/68

CPC分类号： C07K14/005 ,  C12N7/00 ,  C12N2510/02 ,  C12N2770/24221 ,  C12N2770/24222 ,  C12P21/02 ,  G01N33/5767

摘要： A process for screening anti-HCV agents, including the steps of introducing a compound to be tested for its anti-HCV properties with transformed Vero/6418 cells, having a nucleic acid selected from the group consisting of a nucleic acid coding for the structural and non-structural proteins of the HCV, a nucleic acid coding for the non-structural proteins of the HCV, and a replicon containing a resistance gene to an antibiotic and a nucleotide sequence coding for the non-structural proteins of the HCV; extracting total RNA of the cells; and analyzing any reduction of the rate, of synthesis of the RNA of the HCV of the cells relative to a control value corresponding to the rates of synthesis of the RNAs of the HCV of the cells in the absence of the tested compound.

摘要翻译： 一种用于筛选抗HCV药物的方法，包括以下步骤：用转化的Vero / 6418细胞引入待测化合物的抗-HCV特性的化合物，所述方法具有选自编码结构的核酸和 HCV的非结构蛋白，编码HCV的非结构蛋白的核酸和含有抗生素抗性基因的复制子和编码HCV的非结构蛋白的核苷酸序列; 提取细胞的总RNA; 并且相对于在不存在测试化合物的情况下相对于细胞的HCV合成速率的对照值，分析细胞的HCV合成速率的任何降低。